Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rational clinical immunotherapy for multiple sclerosis

S F Hunter1, B G Weinshenker, J L Carter

  • 1Department of Neurology, Mayo Clinic Rochester, Minnesota 55905, USA.

Mayo Clinic Proceedings
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of MOG antibody associated disorders: results of an international survey.

Journal of neurology·2020
Same author

Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up.

Journal of neurology, neurosurgery, and psychiatry·2019
Same author

[MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].

Der Nervenarzt·2018
Same author

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.

Journal of neuroinflammation·2018
Same author

Associations of stream geomorphic conditions and prevalence of alternative reproductive tactics among sockeye salmon populations.

Journal of evolutionary biology·2017
Same author

A population-based prospective study of optic neuritis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2017
Same journal

37-Year-Old Woman With Jaundice.

Mayo Clinic proceedings·2026
Same journal

34-Year-Old Woman With An Unidentified Overdose.

Mayo Clinic proceedings·2026
Same journal

Use of Bronchoscopic Cryobiopsy in Evaluating Interstitial Lung Disease: Radiologic Predictors of Diagnostic Yield and Safety.

Mayo Clinic proceedings·2026
Same journal

Advancing Pulmonary Fibrosis Care: Integrating Genomic Insights Into Clinical Practice.

Mayo Clinic proceedings·2026
Same journal

RAAS Inhibition in the ICU: Stop, Continue, or Restart?

Mayo Clinic proceedings·2026
Same journal

Chronic Kidney Disease-In the Limelight, July 2026.

Mayo Clinic proceedings·2026
See all related articles

Immunotherapy effectively treats multiple sclerosis (MS) exacerbations, reducing their frequency and severity. However, current immunopharmacologic agents have limited impact on progressive MS disability.

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) and other demyelinating diseases are complex neurological conditions.
  • Understanding the role of the immune system is crucial for effective treatment.

Purpose of the Study:

  • To assess the efficacy of immunopharmacologic agents in treating MS and related demyelinating disorders.
  • To provide recommendations for immunotherapeutic strategies.

Main Methods:

  • Review of clinical manifestations of demyelinating diseases.
  • Evaluation of immunotherapeutic goals and individual agent efficacy.
  • Analysis of treatment recommendations based on disease course and disability.

Main Results:

  • Immunotherapy is effective in managing MS and idiopathic demyelinating diseases.

Related Experiment Videos

  • Exacerbations of MS are treatable, with reduced frequency and severity possible.
  • Current immunopharmacologic approaches show minor effects on disability progression in progressive MS.

    • Conclusions:

    • Immunotherapy can effectively manage inflammatory demyelinating diseases, including MS.
    • Diagnosis certainty is essential for initiating immunotherapy.
    • Treatment requires careful consideration of agent limitations, toxicities, and individual patient factors.